Last reviewed · How we verify
NCT03265171
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
trial testing Plasminogen (Human) in Hypoplasminogenemia. No longer available.
Quick facts
| Lead sponsor | Prometic Biotherapeutics, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Plasminogen (Human) — full drug profile →
Conditions studied
- Hypoplasminogenemia — all drugs for Hypoplasminogenemia →
Sponsor
Prometic Biotherapeutics, Inc. — full company profile →
Who can join
16 Months and older, any sex, with Hypoplasminogenemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03265171
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Prometic Biotherapeutics, Inc. trials
Trials by the same sponsor.
- NCT02690714 — A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia · Phase 2, PHASE3 · completed
- NCT02269163 — Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% · Phase 3 · completed
- NCT03642691 — A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial · no longer available
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03265171 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prometic Biotherapeutics, Inc.
- Last refreshed: 24 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03265171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing